Neurofascin 155 IgG4 testing
Pioneering testing yield unparalleled insights
Among patients affected by CIDP, the presence of neurofascin 155 (NF155) IgG4 antibodies indicates a more severe disease presentation and relatively poor treatment response to IVIG, a commonly used first therapy. Using advanced laboratory testing to detect NF155 antibodies, which are found in 4% to 18% of CIDP patients, helps providers solidify diagnosis and choose the best treatment option for patients. Mayo Clinic Laboratories’ NF155 antibody test is the first commercially available CIDP antibody test in the U.S. to use flow cytometry to confirm NF155 IgG4-mediated CIDP.
A Test in Focus
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.
Learn more about how to order this evaluation at your institution.